Skip to Content
Top

BY Scott Merville

A federal task force that gave prostate cancer screening a D grade -- as in don't screen men who have no symptoms of the disease -- should bump that rating to a C, an MD Anderson scientist argues this week in a commentary in the Journal of the American Medical Association.

A grade C more closely fits available clinical evidence and will encourage clinicians to engage men in informed decision-making, a process that the D grade is...

BY Scott Merville

MD Anderson researchers have identified molecular factors that erode the effectiveness of two important drugs for multiple...

BY Scott Merville

Adding a third drug to frontline combination therapy for acute myeloid leukemia resulted in an 85% complete remission...

BY Scott Merville

A promising new class of drugs may shift treatment of the most common form of adult leukemia from combination chemotherapies to a more customized approach.

One such B cell receptor inhibitor, called PCI-32765, continues to show improved effectiveness in an ongoing clinical trial with relatively mild side effects compared to existing treatment.

Susan O'Brien, M.D., professor in MD Anderson's Department of Leukemia, will...

BY Naoto Ueno, M.D., Ph.D., Department of Breast Medical Oncology

Inflammatory breast cancer (IBC) is one of the most aggressive subtypes of breast cancer. The MD Anderson Morgan Welch Inflammatory...

BY Naoto Ueno, M.D., Ph.D., Department of Breast Medical Oncology

Attending the San Antonio Breast Cancer Symposium for the past two years as a member of press is always a very pleasing and rewarding experience...

BY MD Anderson Staff

In an MD Anderson-led study presented at the San Antonio Breast Cancer Symposium today, researchers presented new data about a combination...